Sergio Duron, Ph.D.

Chief Scientific Officer

Sergio Duron brings to COI Pharmaceuticals an excellent track record and over 13 years of drug discovery experience identifying therapeutics for novel targets.

He currently serves as CSO for COI Pharmaceuticals.  He is also CSO for Calporta Therapeutics and vice president of chemistry and drug discovery for Sova Pharmaceuticals, where he leads preclinical drug discovery. He served as vice president of chemistry at Afraxis (partnered with Genentech) and director of chemistry at Zacharon Pharmaceuticals (acquired by Biomarin). He has worked at multiple Avalon Ventures portfolio companies where he helped initiate and direct the drug discovery efforts. Prior to joining the Avalon portfolio companies, Dr. Duron was at Kalypsys, where he was responsible for identifying two IND candidates. Dr. Duron is experienced in multiple therapeutic areas of drug discovery and preclinical development including CNS diseases, orphan diseases, pain and inflammation, metabolic diseases and oncology.

Dr. Duron served as a post-doctoral fellow at The Scripps Research Institute after receiving his Ph.D. in organic chemistry from the University of Illinois at Urbana-Champaign. Dr. Duron received his B.S. in chemistry from the University of Texas at Austin.

Companies

in the news

  • Avalon Ventures and COI Pharmaceuticals Announce Acquisition of Sitari Pharmaceuticals by GSK

    read more
  • A Minute for Celiac Disease

    read more
  • Looking Back on 2016: A Year of Firsts, Financings, and Fun

    read more